MCID: VGT001
MIFTS: 54

Vogt-Koyanagi-Harada Disease

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Vogt-Koyanagi-Harada Disease

MalaCards integrated aliases for Vogt-Koyanagi-Harada Disease:

Name: Vogt-Koyanagi-Harada Disease 12 52 58 54 15
Uveomeningoencephalitic Syndrome 12 43 71
Vogt-Koyanagi-Harada Syndrome 52 36
Uveomenigitic Syndrome 52 58
Vogt-Koyanagi Syndrome 12
Harada's Disease 12
Vkh Syndrome 52
Vkh Disease 52

Characteristics:

Orphanet epidemiological data:

58
vogt-koyanagi-harada disease
Inheritance: Multigenic/multifactorial; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12297
KEGG 36 H01504
ICD9CM 34 363.22 364.24
MeSH 43 D014607
NCIt 49 C85218
SNOMED-CT 67 44923005 47230004
ICD10 32 H20.82 H30.81
ICD10 via Orphanet 33 H20.8 H30.8
UMLS via Orphanet 72 C0042170
Orphanet 58 ORPHA3437
UMLS 71 C0042170

Summaries for Vogt-Koyanagi-Harada Disease

NIH Rare Diseases : 52 Vogt-Koyanagi-Harada disease (VKH disease) is a disease that affects several parts of the body, including the eyes, ears, nervous system, and skin. The signs and symptoms of VKH disease are caused by chronic inflammation of melanocytes. Melanocytes are specialized cells that produce a pigment called melanin . Melanin is the substance that gives skin, hair, and eyes their color. Melanin is also found in other parts of the body, such as the retina of the eyes, where it plays a role in normal vision, and in the inner ear, where it is thought to be involved in hearing. People with VKH disease usually develop vision and hearing problems first, followed by signs of skin problems. The most common symptoms include headaches, inflammation of all layers of the colored part of the eye (panuveitis ), white patches of skin (vitiligo ), hair loss (alopecia ), dizziness and nausea (inner ear related problems), and vision and hearing loss . Neurological symptoms may also occur. The exact cause of VKH disease is not well understood, but research suggests it is an autoimmune disease . It is more common in people with darker skin color including Asian, Middle Eastern, Hispanic, and Native American populations. The disease is treated with corticosteroids and other medications.

MalaCards based summary : Vogt-Koyanagi-Harada Disease, also known as uveomeningoencephalitic syndrome, is related to sympathetic ophthalmia and pars planitis. An important gene associated with Vogt-Koyanagi-Harada Disease is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Bevacizumab and Antineoplastic Agents, Immunological have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and retina, and related phenotypes are sensorineural hearing impairment and cognitive impairment

Disease Ontology : 12 An autoimmune hypersensitivity disease that is caused by T helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis.

KEGG : 36 Vogt-Koyanagi-Harada syndrome (VKHS), initially described as an uveomeningoencephalitic syndrome, is a rare systemic autoimmune disease that targets melanocyte-rich tissues, such as the eye, inner ear, meninges, skin and hair. This disease is characterized by panuveitis, often associated with neurologic and cutaneous manifestations, including headache, hearing loss, vitiligo, and poliosis. VKHS is more common in individuals of pigmented skin, such as Asians, Middle Easterners, Hispanics and Native Americans. Although the exact etiology of VKHS remains unclear, it has also been postulated that such an autoimmune response might be triggered by an infectious agent in a genetically susceptible individual. Several studies have demonstrated that HLA-DR4 is strongly associated with VKHD.

Wikipedia : 74 Vogt-Koyanagi-Harada disease (VKH) is a multisystem disease of presumed autoimmune cause that affects... more...

Related Diseases for Vogt-Koyanagi-Harada Disease

Diseases related to Vogt-Koyanagi-Harada Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 464)
# Related Disease Score Top Affiliating Genes
1 sympathetic ophthalmia 32.0 IL10 HLA-DRB1 HLA-DQA1
2 pars planitis 31.8 HLA-DRB1 HLA-B HLA-A
3 panuveitis 31.7 IL17A IL10 HLA-DRB1 HLA-DQB1 HLA-B CD8A
4 uveitis 31.6 PMEL IL2RA IL17A IL10 IFNG HLA-B
5 optic neuritis 31.5 IL10 HLA-DRB1 HLA-DQA1
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.3 PTPN22 IL17A IL10 IFNG
7 primary adrenal insufficiency 31.3 HLA-DRB1 HLA-DQB1 HLA-DQA1
8 halo nevi 31.2 TYR PMEL HLA-DRB1
9 chickenpox 31.2 IL10 IFNG CD8A
10 meningitis 31.1 IL17A IL10 IFNG HLA-B
11 vitiligo-associated multiple autoimmune disease susceptibility 1 31.1 TYRP1 TYR PTPN22 PMEL NLRP1 HLA-B
12 chorioretinitis 31.1 IL17A IL10 IFNG CD8A
13 relapsing polychondritis 31.0 IL17A IL10 IFNG
14 ulcerative colitis 31.0 IL17A IL10 IFNG HLA-DRB1
15 autoimmune uveitis 31.0 IL17A IL10 IFNG
16 conjunctivitis 31.0 IL10 IFNG HLA-B
17 eye disease 30.9 TYR IL17A IL10 IFNG CD8A
18 proteasome-associated autoinflammatory syndrome 1 30.9 IL17A IL10 IFNG
19 brucellosis 30.9 IL2RA IL17A IL10 IFNG
20 colitis 30.8 IL17A IL10 IFNG HLA-DRB1
21 intermediate uveitis 30.8 IL2RA IL10 IFNG HLA-DRB1 HLA-B
22 fungal meningitis 30.8 IL17A IL10 IFNG CD8A
23 sarcoidosis 1 30.8 IL2RA IFNG HLA-DRB1 HLA-DQB1 HLA-A CD8A
24 spondylitis 30.7 IL17A IL10 IFNG HLA-B
25 reactive arthritis 30.7 IL17A IL10 IFNG HLA-B
26 syphilis 30.7 IL17A HLA-DRB1 FAS CD8A
27 guillain-barre syndrome 30.7 HLA-DRB1 HLA-DQB1 HLA-DQA1 FAS
28 measles 30.6 IL2RA IFNG HLA-DRB1 HLA-DQA1 HLA-A
29 crohn's disease 30.6 PTPN22 IL17A IL10 IFNG HLA-DRB1
30 demyelinating disease 30.6 IL17A IL10 IFNG HLA-DRB1 CD8A
31 autoimmune pancreatitis 30.6 IL17A IL10 HLA-DRB1
32 rheumatic disease 30.6 IL2RA IL10 IFNG HLA-DRB1 HLA-B
33 herpes zoster 30.5 IL10 IFNG HLA-DRB1 HLA-B HLA-A CD8A
34 myasthenia gravis 30.5 PTPN22 IL10 IFNG HLA-DQB1 HLA-B
35 viral hepatitis 30.5 IL10 IFNG HLA-DRB1 HLA-DQA1 FAS
36 bone inflammation disease 30.4 PTPN22 IL17A IL10 IFNG HLA-DRB1 CD8A
37 toxoplasmosis 30.4 NLRP1 IL10 IFNG HLA-DQB1 HLA-DQA1
38 skin disease 30.3 TYR IL17A IL10 IFNG HLA-B CD8A
39 rubella 30.1 IL2RA IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
40 common variable immunodeficiency 29.9 IL2RA IL10 IFNG HLA-B HLA-A FAS
41 immune deficiency disease 29.9 IL2RA IL10 IFNG HLA-B HLA-A FAS
42 psoriasis 29.8 PTPN22 KIR3DL1 IL2RA IL17A IL10 IFNG
43 multiple sclerosis 29.7 PTPN22 IL2RA IL17A IL10 IFNG HLA-DRB1
44 arthritis 29.5 PTPN22 NLRP1 IL17A IL10 IFNG HLA-DRB1
45 autoimmune disease 29.5 PTPN22 NLRP1 IL2RA IL17A IL10 IFNG
46 alopecia areata 29.4 PTPN22 IL2RA IL17A IL10 IFNG HLA-DRB1
47 graves' disease 29.3 PTPN22 IL2RA IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
48 rheumatoid arthritis 28.9 PTPN22 NLRP1 IL2RA IL17A IL10 IFNG
49 diabetes mellitus 28.8 PTPN22 IL2RA IL17A IL10 IFNG HLA-DRB1
50 diabetes mellitus, insulin-dependent 28.8 PTPN22 KIR3DL1 IL2RA IL17A IL10 IFNG

Graphical network of the top 20 diseases related to Vogt-Koyanagi-Harada Disease:



Diseases related to Vogt-Koyanagi-Harada Disease

Symptoms & Phenotypes for Vogt-Koyanagi-Harada Disease

Human phenotypes related to Vogt-Koyanagi-Harada Disease:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sensorineural hearing impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0000407
2 cognitive impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0100543
3 hypopigmented skin patches 58 31 hallmark (90%) Very frequent (99-80%) HP:0001053
4 vitiligo 58 31 hallmark (90%) Very frequent (99-80%) HP:0001045
5 premature graying of hair 58 31 hallmark (90%) Very frequent (99-80%) HP:0002216
6 sparse scalp hair 58 31 hallmark (90%) Very frequent (99-80%) HP:0002209
7 poliosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002290
8 abnormal eyelash morphology 31 hallmark (90%) HP:0000499
9 abnormal eyebrow morphology 31 hallmark (90%) HP:0000534
10 cataract 58 31 frequent (33%) Frequent (79-30%) HP:0000518
11 short stature 58 31 frequent (33%) Frequent (79-30%) HP:0004322
12 visual impairment 58 31 frequent (33%) Frequent (79-30%) HP:0000505
13 glaucoma 58 31 frequent (33%) Frequent (79-30%) HP:0000501
14 retinal detachment 58 31 frequent (33%) Frequent (79-30%) HP:0000541
15 abnormality of the eyelashes 58 Very frequent (99-80%)
16 abnormality of the eyebrow 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

26 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.51 KIR3DL3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.51 HLA-A HLA-B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.51 HLA-A HLA-B HLA-DQA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.51 IL2RA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.51 HLA-A HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.51 HLA-DQA1 IL2RA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.51 KIR3DL3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.51 IL2RA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.51 KIR3DL3
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.51 KIR3DL3 HLA-DQA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.51 KIR3DL3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.51 KIR3DL3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.51 IL2RA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.51 IL2RA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.51 HLA-A HLA-B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.51 IL2RA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.51 KIR3DL3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.51 HLA-A HLA-B HLA-DQA1 IL2RA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.51 KIR3DL3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.51 KIR3DL3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.51 KIR3DL3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.51 IL2RA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.51 KIR3DL3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.51 KIR3DL3 IL2RA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.51 KIR3DL3
26 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.51 KIR3DL3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.51 IL2RA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.51 HLA-A HLA-B KIR3DL3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.51 HLA-DQA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.51 IL2RA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.51 IL2RA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.51 IL2RA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.51 IL2RA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.51 HLA-A HLA-B
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.51 KIR3DL3 HLA-DQA1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.51 HLA-A HLA-B
37 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.51 KIR3DL3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.51 IL2RA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.51 KIR3DL3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.51 HLA-DQA1
41 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 FAS HLA-DQB1 IL10 IL17A IL2RA NLRP1
42 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 FAS HLA-DQB1 IL10 IL17A IL2RA NLRP1

MGI Mouse Phenotypes related to Vogt-Koyanagi-Harada Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.85 CD8A FAS HLA-DQA1 HLA-DQB1 IFNG IL10
2 hematopoietic system MP:0005397 9.73 CD8A FAS HLA-DQA1 HLA-DQB1 IFNG IL10
3 immune system MP:0005387 9.36 CD8A FAS HLA-DQA1 HLA-DQB1 IFNG IL10

Drugs & Therapeutics for Vogt-Koyanagi-Harada Disease

Drugs for Vogt-Koyanagi-Harada Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2 Antineoplastic Agents, Immunological Phase 3
3 Angiogenesis Inhibitors Phase 3
4
Povidone Approved 9003-39-8
5
Iodine Approved, Investigational 7553-56-2 807
6
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
7
Azathioprine Approved 446-86-6 2265
8
Povidone-iodine Approved 25655-41-8
9
Mycophenolic acid Approved 24280-93-1 446541
10
Methylprednisolone Approved, Vet_approved 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved 2921-57-5
12
Prednisolone phosphate Approved, Vet_approved 302-25-0
13
Prednisone Approved, Vet_approved 53-03-2 5865
14
Prednisolone Approved, Vet_approved 50-24-8 5755
15 Prednisolone acetate Approved, Vet_approved 52-21-1
16
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
17
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
18
Prednisolone hemisuccinate Experimental 2920-86-7
19 Anti-Infective Agents
20 Anti-Bacterial Agents
21 Antibiotics, Antitubercular
22 Dermatologic Agents
23 Cyclosporins
24 Antifungal Agents
25 Antirheumatic Agents
26 cadexomer iodine
27 Calcineurin Inhibitors
28 Methylprednisolone Acetate
29 Anti-Inflammatory Agents
30 Hormone Antagonists
31 Antineoplastic Agents, Hormonal
32 glucocorticoids
33 Hormones
34 HIV Protease Inhibitors
35 Antiemetics
36 Gastrointestinal Agents
37
protease inhibitors
38 Autonomic Agents
39 BB 1101
40 Immunologic Factors
41 Immunosuppressive Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation Completed NCT00407121 Phase 3 Bevacizumab
2 Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study Unknown status NCT02015351 bevacizumab
3 Multimodal Analysis and Electroretinogram in VKH From Acute Onset - a Prospective Study Completed NCT03811366 Meticorten
4 Long Term Efficacy of Dexamethasone Intravitreal Implant (Ozurdex®) in Treatment of Recurrent VKH Uveitis Completed NCT03971279 Dexamethasone Ophthalmic implant
5 Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study Recruiting NCT03399175 Early high-dose corticosteroid and immunosuppressive therapy
6 Using Next-Generation Sequencing Technology to Identify Biomarkers of Common Eye Diseases Recruiting NCT04101604
7 Clinical Observational Research on Changes of Peripheral Blood Mononuclear Cell(PBMC) Immunity and Expression Profile in Peripheral Blood of Different Course of of Vogt-Hoyanagi-Harada(VKH) Patients. Recruiting NCT04025476 Steroids
8 Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis Not yet recruiting NCT04126850
9 Subfoveal Choroidal Thickness in Thai Population Terminated NCT02551601

Search NIH Clinical Center for Vogt-Koyanagi-Harada Disease

Cochrane evidence based reviews: uveomeningoencephalitic syndrome

Genetic Tests for Vogt-Koyanagi-Harada Disease

Anatomical Context for Vogt-Koyanagi-Harada Disease

MalaCards organs/tissues related to Vogt-Koyanagi-Harada Disease:

40
Eye, Skin, Retina, T Cells, Brain, Lung, Myeloid

Publications for Vogt-Koyanagi-Harada Disease

Articles related to Vogt-Koyanagi-Harada Disease:

(show top 50) (show all 701)
# Title Authors PMID Year
1
Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. 61 52
25565265 2015
2
Vogt-koyanagi-harada syndrome. 52
18600484 2008
3
Expression of Fas antigen on helper T lymphocytes in Vogt-Koyanagi-Harada disease. 54 61
9646088 1998
4
Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. 54 61
9510558 1998
5
Apoptosis-related fas antigen on memory T cells in aqueous humor of uveitis patients. 54 61
8654110 1996
6
Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. 54 61
7906684 1994
7
Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease. 54 61
1635294 1992
8
A Case of Recurrent Vogt-Koyanagi-Harada Disease Successfully Treated with Adalimumab in Young Female Adult Patient. 61
32037756 2020
9
Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. 61
32016664 2020
10
Lord Nelson's (1758-1805) left eye. 61
28972425 2020
11
Chronological changes of the anterior chamber structure, axial length, and refraction in patients with Vogt-Koyanagi-Harada disease. 61
31973595 2020
12
Multimodal Imaging of Annular Choroidal Detachment in a Patient with Vogt-Koyanagi-Harada Disease. 61
31951785 2020
13
Pigmented paravenous retinochoroidal atrophy associated with Vogt-Koyanagi-Harada disease: a case report. 61
31996165 2020
14
Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease. 61
31928124 2020
15
Rare association between Vogt-Koyanagi-Harada disease and rheumatoid arthritis: Report of a clinical case from the unit of multidisciplinary uveitis. 61
29519769 2020
16
Anesthesia for a patient with Vogt-Koyanagi-Harada disease. 61
31377671 2019
17
Presumed atypical peripapillary Vogt-Koyanagi-Harada disease. 61
31517139 2019
18
Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease. 61
30798260 2019
19
Bilateral serous retinal detachment associated with subretinal fibrin-like material in a case of pregnancy-induced hypertension. 61
31788578 2019
20
[Systemic biological treatment in ophthalmology]. 61
31657252 2019
21
Outcomes of Intravitreal Bevacizumab in Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study. 61
31746659 2019
22
Replication of Genome-Wide Association Analysis Identifies New Susceptibility Loci at Long Noncoding RNA Regions for Vogt-Koyanagi-Harada Disease. 61
31747682 2019
23
Correlation between visual acuity and human leukocyte antigen DRB1*04 in patients with Vogt-Koyanagi-Harada disease. 61
31699055 2019
24
Glucocorticoid Receptor-α and MKP-1 as Candidate Biomarkers for Treatment Response and Disease Activity in Vogt-Koyanagi-Harada Disease. 61
31323199 2019
25
Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis. 61
31440820 2019
26
Impact of Inflammation and Treatment on Self-reported Quality of Life in Patients with Non-acute Vogt-Koyanagi-Harada Disease (VKHD). 61
31671020 2019
27
Choroidal Detachment following an Intravitreal Injection in a Patient with Vogt-Koyanagi- Harada Disease. 61
31664881 2019
28
Photoreceptor stretching: An optical coherence tomography finding in a case of incomplete Vogt-Koyanagi-Harada disease. 61
31942433 2019
29
Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease. 61
31638886 2019
30
Ocular Inflammation and Choroidal Thickness after Pars Plana Vitrectomy in Chronic Recurrent Stage of Vogt-Koyanagi-Harada Disease. 61
31671005 2019
31
Ocular syphilis mimicking Vogt-Koyanagi-Harada disease. 61
31942434 2019
32
Role of Optical Coherence Tomography in the Prognosis of Vogt-Koyanagi-Harada Disease. 61
31577462 2019
33
Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients. 61
30959067 2019
34
Optical coherence tomography diagnostic signs in posterior uveitis. 61
31513851 2019
35
Vogt-Koyanagi-Harada disease. 61
30890584 2019
36
Evaluation of Retinal Pigment Epithelium Layer Change in Vogt-Koyanagi-Harada Disease With Multicontrast Optical Coherence Tomography. 61
31917451 2019
37
Comparison of clinical characteristics in patients with Vogt-Koyanagi-Harada disease with and without anti-retinal antibodies. 61
31065846 2019
38
Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt-Koyanagi-Harada disease (VKH) in Children and Adolescents. 61
31444859 2019
39
Optic Disc Neovascularization in Tubercular Serpiginous-Like Choroiditis. 61
31403829 2019
40
A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl. 61
31409322 2019
41
Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes). 61
30852493 2019
42
Teaching NeuroImages: A case of Vogt-Koyanagi-Harada disease with bilateral retinal detachment. 61
31332094 2019
43
Assessment of measurement methods of posterior inflammation in stromal choroiditis: the value of quantitative outcome measures versus the presently qualitatively based paradigm. 61
29946830 2019
44
Ultra-wide-field angiography findings in acute Vogt-Koyanagi-Harada disease. 61
30100554 2019
45
Clinicopathological and immunohistochemistry correlation in a case of Vogt-Koyanagi-Harada disease. 61
31238472 2019
46
Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy. 61
31268769 2019
47
Sensitivity of indocyanine green angiography compared to fluorescein angiography and enhanced depth imaging optical coherence tomography during tapering and fine-tuning of therapy in primary stromal choroiditis: A case series. 61
31317097 2019
48
Tattoo granulomas with uveitis rather than Vogt-Koyanagi-Harada disease after tattooing? 61
31109485 2019
49
Self-Reported Quality of Life in Patients with Long-Standing Vogt-Koyanagi-Harada Disease. 61
31136253 2019
50
A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab. 61
30616991 2019

Variations for Vogt-Koyanagi-Harada Disease

Expression for Vogt-Koyanagi-Harada Disease

Search GEO for disease gene expression data for Vogt-Koyanagi-Harada Disease.

Pathways for Vogt-Koyanagi-Harada Disease

Pathways related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 PTPN22 NLRP1 KIR3DL2 KIR3DL1 IL2RA IL17A
2
Show member pathways
13.45 PTPN22 KIR3DL2 KIR3DL1 HLA-DRB1 HLA-DQB1 HLA-DQA1
3
Show member pathways
13.35 IL2RA IL17A IL10 IFNG HLA-DRB1 HLA-DQB1
4
Show member pathways
12.91 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
5 12.76 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
6
Show member pathways
12.65 IL2RA IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
7
Show member pathways
12.63 IL2RA IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B
8
Show member pathways
12.59 IL17A IL10 IFNG FAS CD8A
9
Show member pathways
12.53 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
10
Show member pathways
12.5 KIR3DL2 KIR3DL1 IFNG HLA-B HLA-A FAS
11
Show member pathways
12.49 IL2RA IL17A IL10 IFNG HLA-DRB1 HLA-DQB1
12
Show member pathways
12.36 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
13
Show member pathways
12.32 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1
14 12.29 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
15
Show member pathways
12.28 IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
16
Show member pathways
12.27 IL2RA IL17A IL10 IFNG HLA-B HLA-A
17 12.25 IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
18
Show member pathways
12.21 KIR3DL3 KIR3DL2 KIR3DL1 IL2RA IL17A IL10
19 12.15 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
20 12.07 PTPN22 NLRP1 IL2RA IL17A IL10 IFNG
21 12.06 KIR3DL2 KIR3DL1 HLA-B HLA-A CD8A
22 12.01 IL2RA IL10 IFNG CD8A
23
Show member pathways
11.97 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1
24
Show member pathways
11.95 IL2RA IFNG HLA-DRB1 HLA-A CD8A
25 11.91 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
26 11.85 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1 CD8A
27 11.8 IL17A IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
28 11.8 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A CD8A
29
Show member pathways
11.78 HLA-DRB1 HLA-DQB1 HLA-DQA1
30 11.72 IL10 IFNG CD8A
31 11.69 IL17A IL10 IFNG
32 11.67 IL2RA IL17A IL10 IFNG CD8A
33
Show member pathways
11.66 IL2RA IFNG HLA-A CD8A
34 11.51 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1 CD8A
35 11.5 IL2RA IL10 IFNG
36 11.39 IL10 IFNG FAS
37 11.28 IL10 IFNG HLA-DRB1
38 11.25 IL2RA IFNG HLA-DRB1
39 10.36 TYRP1 TYR

GO Terms for Vogt-Koyanagi-Harada Disease

Cellular components related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.17 TYRP1 TYR PMEL KIR3DL3 KIR3DL2 KIR3DL1
2 external side of plasma membrane GO:0009897 9.8 IL2RA IL17A HLA-DRB1 HLA-B CD8A
3 endosome membrane GO:0010008 9.78 TYRP1 HLA-DRB1 HLA-DQB1 HLA-DQA1
4 trans-Golgi network membrane GO:0032588 9.67 HLA-DRB1 HLA-DQB1 HLA-DQA1
5 endocytic vesicle membrane GO:0030666 9.61 HLA-DRB1 HLA-DQB1 HLA-DQA1
6 transport vesicle membrane GO:0030658 9.54 HLA-DRB1 HLA-DQB1 HLA-DQA1
7 melanosome membrane GO:0033162 9.51 TYRP1 TYR
8 MHC class I protein complex GO:0042612 9.46 HLA-B HLA-A
9 clathrin-coated endocytic vesicle membrane GO:0030669 9.46 TYRP1 HLA-DRB1 HLA-DQB1 HLA-DQA1
10 MHC class II protein complex GO:0042613 9.43 HLA-DRB1 HLA-DQB1 HLA-DQA1
11 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A

Biological processes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 PTPN22 NLRP1 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
2 T cell receptor signaling pathway GO:0050852 9.8 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1
3 regulation of immune response GO:0050776 9.8 KIR3DL2 KIR3DL1 HLA-B HLA-A CD8A
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.73 HLA-DRB1 HLA-DQB1 HLA-DQA1
5 negative regulation of T cell proliferation GO:0042130 9.63 IL2RA IL10 HLA-DRB1
6 interferon-gamma-mediated signaling pathway GO:0060333 9.63 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
7 positive regulation of MHC class II biosynthetic process GO:0045348 9.55 IL10 IFNG
8 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.54 HLA-B HLA-A
9 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.54 HLA-DRB1 HLA-DQB1 HLA-DQA1
10 protection from natural killer cell mediated cytotoxicity GO:0042270 9.52 HLA-B HLA-A
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.51 HLA-DRB1 HLA-DQB1
12 melanin biosynthetic process GO:0042438 9.5 TYRP1 TYR PMEL
13 positive regulation of interleukin-23 production GO:0032747 9.48 IL17A IFNG
14 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.43 HLA-DRB1 HLA-DQB1
15 antigen processing and presentation GO:0019882 9.43 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A CD8A
16 immune response GO:0006955 9.4 KIR3DL1 IL2RA IL17A IL10 IFNG HLA-DRB1

Molecular functions related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monophenol monooxygenase activity GO:0004503 9.16 TYRP1 TYR
2 MHC class II receptor activity GO:0032395 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
3 peptide antigen binding GO:0042605 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A

Sources for Vogt-Koyanagi-Harada Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....